# The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

> **NCT02269267** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 173 (actual)

## Conditions studied

- Leukemia, Myeloid, Chronic

## Interventions

- **DRUG:** Imatinib (Stopping their TKI)
- **DRUG:** Dasatinib (Stopping their TKI)
- **DRUG:** Nilotinib (Stopping their TKI)
- **DRUG:** Bosutinib (Stopping their TKI)

## Key facts

- **NCT ID:** NCT02269267
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-18
- **Primary completion:** 2021-04-06
- **Final completion:** 2022-04-06
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2023-03-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269267, "The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02269267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*